KLRA
NASDAQKailera Therapeutics Inc.
$25.03+0.86 (+3.56%)
News22/Ratings0
Price$25.03-0.04 (-0.16%)
01:45 PM07:45 PM
News · 26 weeks22+100%
2025-10-262026-04-19
Mix2290d
- Insider17(77%)
- Other3(14%)
- Offering1(5%)
- SEC Filings1(5%)
Latest news
22 items- SECSEC Form SCHEDULE 13D filed by Kailera Therapeutics Inc.SCHEDULE 13D - Kailera Therapeutics, Inc. (0002096997) (Subject)
- SECSEC Form SCHEDULE 13D filed by Kailera Therapeutics Inc.SCHEDULE 13D - Kailera Therapeutics, Inc. (0002096997) (Subject)
- INSIDERSEC Form 4 filed by Rtw Investments, Lp4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
- INSIDERSEC Form 4 filed by Jiangsu Hengrui Pharmaceuticals Co., Ltd.4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
- PRHengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit GrowthSHANGHAI, April 22, 2026 /PRNewswire/ -- Hengrui Pharma reported steady growth in the first quarter of 2026. In Q1 2026, the Company recorded revenue of RMB 8.14 billion, up 12.98% year-over-year, while net profit attributable to shareholders increased by 21.78% to RMB 2.28 billion. Innovative drugs remained the key growth driver, generating RMB 4.53 billion in revenue, up 25.75% year-over-year and accounting for 61.69% of total pharmaceutical sales. The Company continued to advance its innovation-driven strategy with sustained R&D investment and solid pipeline progress. R&D investments in Q1 2026 totaled RMB 2.22 billion, representing for approximately 27.32% of revenue.During the period, t
- INSIDERSEC Form 4 filed by Bain Capital Investors Llc4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
- INSIDERSEC Form 4 filed by Koppel Adam4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
- INSIDERSEC Form 4 filed by Bain Capital Life Sciences Investors, Llc4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
- INSIDERSEC Form 4 filed by Kaplan Andrew T.4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
- INSIDERSEC Form 4 filed by Cloghessy Paula4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
- INSIDERSEC Form 4 filed by Akamine Scott4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
- INSIDERSEC Form 4 filed by Renaud Ronald C Jr4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
- INSIDERSEC Form 4 filed by Burgess Paul D.4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
- INSIDERSEC Form 4 filed by Milligan John F4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
- INSIDERSEC Form 4 filed by Coleman Jamie Beth4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
- INSIDERSEC Form 4 filed by Mackay Martin4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
- INSIDERSEC Form 4 filed by Wasserman Scott M.4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
- INSIDERSEC Form 4 filed by Hite Christopher4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
- INSIDERSEC Form 4 filed by Clyburn Frank4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
- INSIDERSEC Form 4 filed by Pagan Douglas W.4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)
- SECSEC Form 8-K filed by Kailera Therapeutics Inc.8-K - Kailera Therapeutics, Inc. (0002096997) (Filer)
- PRKailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesWALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (NASDAQ:KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the closing of its initial public offering of 44,921,875 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 5,859,375 additional shares, at the initial public offering price of $16.00 per share. All of the shares of common stock were offered by Kailera. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $718.8 million. Kailera's